

Remarks

Amendments to Specification

Applicants request entry of the amendments to the specification in this Preliminary Amendment. Applicants submit that these amendments do not introduce any new matter.

Response to Restriction Requirement

A restriction requirement was issued on April 27, 2004. Applicants submit that this restriction requirement is rendered moot by the Preliminary Amendment A that Applicants filed with this patent application on September 5, 2004. Specifically, the Preliminary Amendment A restricts the recited compounds to those of Formula 122-1 wherein E³ represents a carbocycle (*i.e.*, Group III), and requests that the Examiner use the compound of claim 222 as the starting point for examination.

Call on May 4, 2004 Between the Examiner and Undersigned

The Examiner and Undersigned discussed the restriction requirement during a May 4, 2004 telephone call. During that call, the Undersigned pointed out that Applicants' September 5, 2004 Preliminary Amendment A had already restricted the claims pursuant to the April 11, 2003 restriction requirement in the parent application. Applicants and the Undersigned thank the Examiner for her courtesy during the call.

* * * * *

Applicants request consideration on the merits of the above-referenced patent application, and submit that the pending claims are in condition for allowance. Applicants do not believe that they owe any fee in connection with this filing. If, however, Applicants do owe any such fee(s), the Commissioner is hereby authorized to charge the fee(s) to Deposit Account No. **08-0750**. In addition, if there is ever any other fee deficiency or overpayment under 37 C.F.R. §1.16 or 1.17 in connection with this patent application, the Commissioner is hereby authorized to charge such deficiency or overpayment to Deposit Account No. **08-0750**.

Amendment C and
Response to Restriction Requirement
Appl. No. 10/657,034
May 5, 2004

The Examiner is requested to call the undersigned if any questions arise that can be addressed over the phone to expedite examination of this application.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'D. Gryte', with a large, stylized initial 'D' and a long horizontal stroke extending to the right.

David M. Gryte, PTO Reg. No. 41,809
Harness, Dickey & Pierce
Suite 400, 7700 Bonhomme
Clayton, Missouri 63105
(314) 726-7500 (tel)
(314) 726-7501 (fax)

Appendix A
Marked-Up Version of Amendments to Specification

Please replace paragraph 785 on page 196 with the following paragraph:

[785] The term "heteroaryl" (alone or in combination with another term(s)) means an aromatic heterocyclyl containing from 5 to 14 ring atoms. A heteroaryl may be a single ring or 2 or 3 fused rings. Examples of heteroaryl substituents include 6-membered ring substituents such as pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, and 1,3,5-, 1,2,4-, and 1,2,3-triazinyl; 5-membered ring substituents such as imidazolyl, furanyl, thiophenyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, 1,2,3-, 1,2,4-, 1,2,5-, or 1,3,4-oxadiazolyl and isothiazolyl; 6/5-membered fused ring substituents such as benzothiofuranyl, isobenzothiofuranyl, benzisoxazolyl, benzoxazolyl, purinyl, and anthranilyl; and 6/6-membered fused rings such as quinolinyl, isoquinolinyl, ~~and 1,4-benzoxazinyl (including~~ cinnolinyl, and quinazolinyl [I]).

Please replace paragraph 1064 on page 291 with the following paragraph:

[1064] The study of angiogenesis depends on a reliable and reproducible model for the stimulation and inhibition of a neovascular response. The corneal micropocket assay provides such a model of angiogenesis in the cornea of a mouse. See, Kenyon, B.M., et al., "A Model of Angiogenesis in the Mouse Cornea", Investigative Ophthalmology & Visual Science, Vol. 37, No. 8, pp. 1625-1632 (July 1996).